Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 7/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | DNM1L | O00429 | 2/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12036168 | 0.87 | BAZ2A (0.44) | GPR119SLC6A3HRH3AOC3DNM1L | |
| SCHEMBL1269354 | 0.87 | SLC6A3 (0.40) | GPR119SLC6A3FAAHAOC3DNM1L | |
| SCHEMBL1118089 | 0.87 | SLC6A3 (0.40) | GPR119SLC6A3FAAHAOC3DNM1L | |
| SCHEMBL1774781 | 0.82 | AOC3 (0.50) | GPR119SLC6A3FAAHAOC3DNM1L | |
| SCHEMBL3144261 | 0.82 | GPR119 (0.60) | GPR119HRH3 | |
| SCHEMBL9046241 | 0.81 | SLC6A3 (0.47) | GPR119SLC6A3HRH3AOC3DNM1L | |
| SCHEMBL1270245 | 0.80 | KMT2A (0.44) | GPR119SLC6A3FAAHAOC3DNM1L | |
| SCHEMBL2952296 | 0.79 | CASP8 (0.42) | FAAH | |
| SCHEMBL17541543 | 0.79 | HSD11B1 (0.47) | FAAHBAZ2A | |
| SCHEMBL1047470 | 0.79 | GPR119 (0.37) | GPR119SLC6A3HRH3AOC3DNM1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | PI INDUSTRIES LTD. (IN) | 2026-03-17 | — | — | US | disclosed |
| CN-115052875-B | 4- (4, 5-Dihydroisoxazol-3-yl) thiazol-2-yl) piperidine-thioimine or sulphoxide-imine derivatives and related compounds as fungicides for crop protection | PI工业有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4058450-B1 | 4-(4-(4,5-DIHYDROISOXAZOL-3-YL)THIAZOL-2-YL)PIPERIDINE SULFILIMINE AND SULFOXIMINE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES FOR CROP PROTECTION | PI INDUSTRIES LTD (IN) | 2024-07-03 | — | — | EP | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230012782-A1 | NOVEL SULFILIMINES OR SULFOXIMINES CONTAINING FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI INDUSTRIES LTD. (IN) | 2023-01-19 | — | — | US | disclosed |
| EP-4058450-A2 | 4-(4-(4,5-DIHYDROISOXAZOL-3-YL)THIAZOL-2-YL) PIPERIDINE SULFILIMINE AND SULFOXIMINE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES FOR CROP PROTECTION | PI Industries Ltd. (IN) | 2022-09-21 | — | — | EP | disclosed |
| CN-115052875-A | 4- (4- (4, 5-dihydroisoxazol-3-yl) thiazol-2-yl) piperidinethimine or sulfoximine derivatives as fungicides for crop protection and related compounds | PI工业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021094903-A1 | 1-(4-(4-(5-PHENYL-4,5-DIHYDROISOXAZOL-3-YL)THIAZOL-2-YL)PIPERIDIN-1-YL)-ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES FOR CROP PROTECTION | PI INDUSTRIES LTD. (IN) | 2021-05-20 | — | — | WO | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| CN-111655687-A | Novel fungicidal heterocyclic compounds | PI工业有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3243826-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| EP-2841437-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9688695-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-02 | — | — | US | disclosed |
| EP-2841437-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013163279-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130090476-A1 | Thiazolylpiperidine Derivatives as Fungicides | BAYER CROPSCIENCE AG (DE) | 2013-04-11 | — | — | US | disclosed |
| US-20130090477-A1 | Thiazolylpiperidine Derivatives as Fungicides | BAYER CROPSCIENCE AG (DE) | 2013-04-11 | — | — | US | disclosed |
| US-20110046178-A1 | Thiazolylpiperidine Derivatives as Fungicides | BAYER CROPSCIENCE AG (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012782-A1 | NOVEL SULFILIMINES OR SULFOXIMINES CONTAINING FUNGICIDAL HETEROCYCLIC COMPOUNDS | SULT1E1, SULT1A1, STS | GPR119 1838/4885SLC6A3 1750/4885HRH3 56/4885 |
| US-20130090476-A1 | Thiazolylpiperidine Derivatives as Fungicides | NAT1, GRHPR, PTPRG | GPR119 428/4885SLC6A3 3409/4885HRH3 2909/4885 |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | GPR119 684/4885SLC6A3 1513/4885HRH3 105/4885 |
| US-20130090477-A1 | Thiazolylpiperidine Derivatives as Fungicides | NAT1, GRHPR, PTPRG | GPR119 428/4885SLC6A3 3409/4885HRH3 2909/4885 |
| US-20110046178-A1 | Thiazolylpiperidine Derivatives as Fungicides | NAT1, GRHPR, PTPRG | GPR119 428/4885SLC6A3 3409/4885HRH3 2909/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | GPR119 684/4885SLC6A3 1513/4885HRH3 105/4885 |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | GPR119 682/4885SLC6A3 1502/4885HRH3 104/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | GPR119 682/4885SLC6A3 1502/4885HRH3 104/4885 |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | SULT1E1, CBR1, SULT1A1 | GPR119 3842/4885SLC6A3 1112/4885HRH3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.